Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation

Transplant Infectious Disease

Volumn 16, Issue 3, 2014, Pages 369-378

  Freire, M P ^a   Van Der Heijden, I M ^a   do Prado, G V B ^a   Cavalcante, L S ^a   Boszczowski, I ^a   Bonazzi, P R ^a   Rossi, F ^a   Guimaraes T ^a   D'Albuquerque, L A C ^a   Costa, S F ^a   Abdala, E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acinetobacter baumannii; CRAB; Early infection; Liver transplantation; Multidrug resistance; Polymyxin; PRAB

Indexed keywords

AMPICILLIN; CARBAPENEM; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; GENTAMICIN; POLYMYXIN; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BLOODSTREAM INFECTION; BROTH DILUTION; CLONAL VARIATION; DESCRIPTIVE RESEARCH; DIALYSIS; FEMALE; HUMAN; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MELD SCORE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMYXIN RESISTANT ACINETOBACTER BAUMANNII INFECTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; SCORING SYSTEM; SURGICAL INFECTION; SURGICAL MORTALITY; ACINETOBACTER BAUMANNII; CASE CONTROL STUDY; DRUG COMBINATION; DRUG EFFECTS; HETEROZYGOTE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARRIER STATE; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMYXINS;

EID: 84902011022     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12210     Document Type: Article

References (37)

1. Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transpl 2001; 7 (1): 22-26.
2. Moreno A, Cervera C, Gavaldá J, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant 2007; 7 (11): 2579-2586.
3. Zhong L, Men TY, Li H, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation - spectrum and risk factors. J Infect 2012; 64 (3): 299-310.
4. Mrzljak A, Peric Z, Kovacevic V, Gustin D, Vrhovac R, Andrasevic AT. Rising problem of multidrug-resistant gram-negative bacteria causing bloodstream infections after liver transplantation: how should we handle the issue? Liver Transpl 2010; 16 (10): 1217-1219.
5. Bert F, Larroque B, Paugam-Burtz C, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl 2010; 16 (3): 393-401.
6. Soong RS, Chan KM, Chou HS, et al. The risk factors for early infection in adult living donor liver transplantation recipients. Transplant Proc 2012; 44 (3): 784-786.
7. Kim YJ, Yoon JH, Kim SI, et al. High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 2011; 43 (6): 2397-2399.
8. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010; 12 (1): 87-93.
9. Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment. Diagn Microbiol Infect Dis 2011; 70 (2): 246-252.
10. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008; 13 (47): 19045: pii.
11. Hancock RE. Peptide antibiotics. Lancet 1997; 349: 418-422.
12. Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55 (7): 3370-3379.
13. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53 (9): 3628-3634.
14. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54 (12): 4971-4977.
15. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45 (5): 594-598.
16. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52 (1): 351-352.
17. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011; 204 (7): 1146-1147.
18. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 2011; 204 (7): 1147-1148.
19. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Information supplement. Clinical and Laboratory Standards Institute. CLSI document M100-S21, vol. 31, no.1; January 2011.
20. Tenover F, Arbeit R, Goering R, et al. interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strains typing. J Clin Microbiol 1995; 33: 2233-2239.
21. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36 (5): 309-332.
22. Karvellas CJ, McPhail M, Pink F, et al. Bloodstream infection after elective liver transplantation is associated with increased mortality in patients cirrhosis. J Crit Care 2011; 26: 468-474.
23. Shi SH, Kong HS, Xu J, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11 (5): 405-412.
24. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007; 65 (3): 204-211.
25. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int J Antimicrob Agents 2008; 32 (2): 106-119.
26. Park YK, Jung SI, Park KH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009; 64 (1): 43-51.
27. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008; 32 (5): 450-454.
28. Bergen PJ, Forrest A, Bulitta JB, et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55 (11): 5134-5142.
29. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52 (1): 333-336.
30. Zhang L, Dhillon P, Yan H, Farmer S. Hancock RE. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3317-3321.
31. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9: 23-37.
32. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36 (3): 807-811.
33. Valencia R, Arroyo LA, Conde M, et al. Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect Control Hosp Epidemiol 2009; 30 (3): 257-263.
34. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15 (6): 980-982.
35. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (8): 3430-3436.
36. Fernandez-Reyes M, Rodriguez-Falcon M, Chiva C, Pachon J, Andreu D, Rivas L. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 2009; 9: 1632-1645.
37. López-Rojas R, Domínguez-Herrera J, McConnell MJ, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011; 203 (4): 545-548.